Proteinuria-Lowering Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Chronic Kidney Disease Patients: A Real-World Multicentric Study

Control of dyslipidemia in chronic kidney disease (CKD) is not always guaranteed with statins and/or ezetimibe. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have opened up a new era in lipid control, but their effect on renal function and proteinuria in real life have not yet be...

Descripción completa

Detalles Bibliográficos
Autores principales: Muñoz Ramos, Patricia, Gil Giraldo, Yohana, Álvarez-Chiva, Vicente, Arroyo, David, Sango Merino, Cristina, Moncho Francés, Francesc, Ocaña, Javier, Reque, Javier, Sánchez-Álvarez, Emilio, Górriz, José Luis, Quiroga, Borja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8618891/
https://www.ncbi.nlm.nih.gov/pubmed/34822418
http://dx.doi.org/10.3390/metabo11110760

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8618891/
https://www.ncbi.nlm.nih.gov/pubmed/34822418
http://dx.doi.org/10.3390/metabo11110760

Ejemplares similares